PARADIGM-HF trial: will LCZ696 change the current treatment of systolic heart failure? - Wikidata - awgldk - TriplyDB

PARADIGM-HF trial: will LCZ696 change the current treatment of systolic heart failure?

PARADIGM-HF trial: will LCZ696 change the current treatment of systolic heart failure?

http://www.wikidata.org/entity/Q36162163

about

Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date Changing the treatment of heart failure with reduced ejection fraction: clinical use of sacubitril-valsartan combination

P2860

Q28070064-DDDE1F9E-1ADA-4FC6-84FF-74DF69933C12 Q37597972-0A758CF5-4571-44AF-AF78-230A3F45D4C4

P2860

PARADIGM-HF trial: will LCZ696 change the current treatment of systolic heart failure?

http://www.wikidata.org/entity/Q36162163

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

PARADIGM-HF trial: will LCZ696 change the current treatment of systolic heart failure?

@ast

PARADIGM-HF trial: will LCZ696 change the current treatment of systolic heart failure?

@en

type

label

PARADIGM-HF trial: will LCZ696 change the current treatment of systolic heart failure?

@ast

PARADIGM-HF trial: will LCZ696 change the current treatment of systolic heart failure?

@en

prefLabel

PARADIGM-HF trial: will LCZ696 change the current treatment of systolic heart failure?

@ast

PARADIGM-HF trial: will LCZ696 change the current treatment of systolic heart failure?

@en

P1433

Q36162163-AD86B472-E619-4CD2-B3A2-89B6A29DDC20

P1476

Q36162163-B4AE4153-979B-4F28-BC59-9A7A5D0F8384

P2093

Q36162163-17BAD179-3C35-4553-BD85-3165EF59BF0E

P2860

Q36162163-41684C1D-6BC7-40BB-8801-4F50BD458F8A

Q36162163-4F78DFE6-DB1D-4121-954D-9DC2C89EEF5A

Q36162163-66D02BB0-9C60-4B57-A60F-670A16994683

Q36162163-68667DD9-F4B6-4E3A-BEF1-5F9C1E9D5960

Q36162163-6BA3F8C7-4EF6-48F3-B28C-432E24ADFBC8

Q36162163-82B6C32C-3030-4DE7-8D87-F18E1426A91E

Q36162163-B37C7F1C-2846-4DD5-8918-4EF70E3C48E9

Q36162163-B4821E01-B2BB-496F-A67B-217C271CEB3A

Q36162163-BAB02D5B-B683-4BA4-BA6C-B44E5C8F8AF2

Q36162163-C53AF0C1-A2A7-4704-9CA6-3FED1AE6CA84

P304

Q36162163-18CB1A7F-88B2-4E55-AADC-5BD36EF8976D

P31

Q36162163-846821b7-8720-437a-8d40-8f787121ad58

Q36162163-A9256143-37E5-4656-8D64-D3575D035A49

P356

Q36162163-23FCFAA7-7642-4BD7-8521-D3BE2CBDB0A4

P433

Q36162163-44DCAED1-6EFD-45A6-8342-DD511A831ED1

P478

Q36162163-DE004098-1B24-4B8B-AE13-1C8587BF31BF

P577

Q36162163-AD4C4815-294E-4061-B46D-23401F73D74E

P5875

Q36162163-3B9BAF78-2D84-49C0-A293-98C5E7C37ED6

P698

Q36162163-3C541F2D-FFA0-44D0-B0C1-6A06077F5063

P921

Q36162163-373862E8-F544-4E86-8346-5C210179E867

P932

Q36162163-730D2CC5-C304-4F4C-A69D-E8F67C833CB1

P356

J.ISSN.1671-5411.2015.05.010

P1433

Journal of Geriatric Cardiology

P1476

PARADIGM-HF trial: will LCZ696 change the current treatment of systolic heart failure?

@en

P2093

Edgardo Kaplinsky

http://www.w3.org/2001/XMLSchema#string

P2860

Epidemiology and risk profile of heart failure

2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: de

Angiotensin-neprilysin inhibition versus enalapril in heart failure

The natriuretic peptides in heart failure: diagnostic and therapeutic potentials.

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.

Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema.

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).

P304

470-473

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.11909/J.ISSN.1671-5411.2015.05.010

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2015-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

283324123

http://www.w3.org/2001/XMLSchema#string

P698

26512236

http://www.w3.org/2001/XMLSchema#string

P921

P932

4605940

http://www.w3.org/2001/XMLSchema#string